Dialysis world news


Dialysis on demand: Outset Medical raises $60M for simple at-home device that ... - MedCity News

Outset MedicalBay Area startup Outset Medical has built an at-home hemodialysis machine that’s meant to be simple for consumers with kidney failure to use – and has raised an impressive swath of capital to do so.

The Warburg Pincus-backed Outset just raised nearly $60 million dollars in an apparent Series B round, according to regulatory filings. However, a spokeswoman for the company said this isn’t the complete amount and will release a more accurate funding figure in the coming weeks. She didn’t comment further on the fundraise.

Why an at-home hemodialysis device? The standard process is quite cumbersome: Patients with kidney failure typically have to go to a clinic three times a week, and sit still for several hours while their blood is cleaned.

There’s been a movement to allow patients to undergo dialysis at home – but even then, the training time takes up to two months. It’s not exactly simple.

Outset’s blood-filtering device, called the Tablo, filters and purifies regular tap water, creates dialysate, takes a patient’s blood pressure and deliver medication.

It touts a simple user interface: With a touchscreen display, it offers step-by-step pictures and “conversational instructions that make it hard to mess up no matter how new a patient, or caregiver, may be to dialysis.” It’s in a compact, table-height device, Outset says – no hospital poles or additional equipment.

“We’ve set out to give people their time back,” Outset says of its device. “Tablo dramatically reduces the time involved in setting up and managing dialysis, whether at home in in clinic. There is simply less to do and less to learn.”

The device already has FDA clearance for use in clinics and hospitals, and is still working for approval in home use. It’s enrolling patients in clinical trials for at-home use this year.

This is a Warburg Pincus Ventures-backed company, launched in 2010, with two board of directors and CEO Leslie Trigg hailing from the private equity firm. Another listed investor is The Vertical Group, though this $60 million filing indicates 11 investors participated in the new round.

Warburg Pincus says Outset Medical’s competing in a $13 billion worldwide dialysis market. It writes about the Tablo:

With the dialysis patient population growing and dialysis reimbursement declining, Outset’s Tablo Hemodialysis System is aimed specifically at lowering costs for dialysis providers and meaningfully improving the care experience for patients.

The company’s clearly got aims to hit it big among consumers – check out the slick marketing in this video explaining the Tablo:

According to previous regulatory filings, it looks as though prior to this large fundraise, the company’s brought in about $9.5 million.

[PHOTO: Outset Medical]

 

...

 
Dialysis Patient With Concealed Gun Fends Off Early Morning Armed Robbery ... - Daily Caller

A would-be robber armed with a gun who targeted a Michigan dialysis patient earlier this week was forced to retreat after his intended victim pulled out a gun of his own.

Shortly before 5 a.m. Monday, a 49-year-old Waterford man pulled up to DaVita Dialysis where he was to receive early morning dialysis treatment, My Fox Detroit reported.

As the patient exited his vehicle, a man approached from a wooded area and demanded his wallet. When the patient refused, the suspect pulled a gun from his hoodie and demanded the wallet again.

Rather than cough it up, the patient told police he pulled out his own gun and pointed it at the suspect.

“Do you really want to do this?” he asked.

The suspect apparently determined that he did not want to do that.

“Have a nice day,” he shouted as the man fled the scene.

The self-defending dialysis patient then went into the clinic for treatment and called police.

WATCH:

Fox 2 News Headlines

Follow Chuck on Twitter

...

 
#AUA15 - Medical comorbidities, not neoadjuvant chemotherapy, affects decline ... - UroToday
image

NEW ORLEANS, LA USA (UroToday.com) - Despite level I evidence showing an improved overall survival in patients undergoing neoadjuvant chemotherapy (NAC), only about 20% of muscle-invasive bladder cancer (MIBC) patients undergo NAC in the United States. Patients who were eligible for NAC can become ineligible for cisplatin-based adjuvant chemotherapy (AC) if the renal function declines to GFR < 50 after radical cystectomy (RC). The group from Fox Chase Cancer Center sought to determine patient demographic and comorbidity history, including the use of NAC, impacting the decline of renal function to a threshold where platinum-based AC is no longer feasible.

auaThree hundred fifteen patients underwent RC between 2006 and 2011 and were identified from the institutional registry. Patients were included if their GFR was > 50 preop and they had a pathological diagnosis of primary urothelial MIBC. Adjusting for patient variables (age, gender, race), comorbidities (preop anticoagulation, CAD, afib/MI/PE, HTN, DM, DVT), receipt of NAC, intraoperative factors (EBL) and postoperative factors (Length of stay), logistic regressions were used to examine the determinants of eGFR < 50 measured anytime within 3 months postoperatively.

One hundred eighty-seven patients met criteria. Fifty-seven underwent NAC, and 130 patients did not. Of patients without NAC, 39 patients experienced a decline in eGFR < 50 (30%). On univariate analysis, presence of DM (OR 2.41, 95% CI 1.07-5.46) and presence of HTN (OR 2.37, 95% CI 1.24-4.53) were the only factors associated with increased risk of GFR decline < 50. In a multivariable model, only HTN (OR 2.26, 95% CI 1.05-4.84) was associated with increased risk. Receipt of NAC was not associated with GFR decline in either adjusted or unadjusted models.

The group concludes that up to 30% of patients with normal GFR preoperatively may become ineligible for platinum-based systemic therapy after RC based on renal function decline alone. Patients with medical comorbidities such as HTN and DM are particularly sensitive to this decline and should be encouraged to undergo NAC.

Presented and reported by Mohammed Haseebuddin, MD at the American Urological Association (AUA) Annual Meeting - May 15 - 19, 2015 - New Orleans, LA USA

Fox Chase Cancer Center, Philadelphia, PA USA

 

...

 
The Insider, Javier Rodriguez Unloaded 36466 Shares of DaVita HealthCare ... - OctaFinance.com

The Insider, Javier Rodriguez Unloaded 36466 Shares of DaVita HealthCare ... - OctaFinance.com

Javier Rodriguez Insider Sell Transaction

A few days ago, the CEO – Kidney Care of DaVita HealthCare Partners Inc (NYSE:DVA) 83.70 +0.50 0.60%, Mr. Javier Rodriguez, unloaded a significant amount company shares – 36,466, amounting to $2,972,001 U.S Dollars, based on an average weighted cost of $81.5 per share. It seems he is very active lately as in the last month, he unloaded additional 20,946 shares of the company, worth $1,771,403 USD. This transaction was pretty big one, so clearly it won’t go unnoticed. At the moment, Javier Rodriguez has rights to a total of 100,730 shares or 0.05% of the company’s market cap.

Davita Healthcare Partners Inc Stock Rating, Sentiment and Fundamentals

This move by Javier has led us to believe that the Company is expensive, with chances of the stock price going down. If Davita Healthcare Partners Inc posts $3.77 per share as forecasted by fifteen expert security analysts, Davita Healthcare Partners Inc will have 22.07 forward PE. Their expectations put the year-over-year earnings-per-share growth rate at 12.50%.

* Read How Our Stock Ratings System Works

Despite Javier Rodriguez’s trade, we have no choice but to rate the stock NEUTRAL as our trend following model as illustrated on the chart below, is flashing Buy. Davita Healthcare Partners Inc has seen its stock price increasing by up to 16.56% in the last 200 days, and currently the stock is in a reliable up trend.

Price Chart of Davita Healthcare Partners NYSE:DVA Stock

The Insider, Javier Rodriguez Unloaded 36466 Shares of DaVita HealthCare ... - OctaFinance.com

Source: RightEdgeSystems, Yahoo Split & Dividend Adjusted Data and OctaFinance Interpretations

The dated 19-05-2015 transaction’s document submitted with the (SEC) is freely accessible here.

Hedge Funds Ownership

According to SEC 13F filings for Q4 2014, 468 investment managers own shares of Davita Healthcare Partners Inc. In the last quarter, Davita Healthcare Partners Inc had 197.62% institutional ownership. That is a very high interest. Its up 140.93% from previous quarter. These institutional investors increased the total shares they own by 248.54 million to 424.89 million this quarter. A total of 30 funds closed their positions in Davita Healthcare Partners Inc and 158 reduced their holdings. There were 50 funds that created new positions and 189 funds that added to their positions.

16 hedge funds are positive about the stock and have it in their Top 10. Some of them are: Foundation Asset Management Lp, Swift Run Capital Management Llc, Summit Partners L P, Timessquare Capital Management Llc, Cognios Capital Llc, Triple Frond Partners Llc, Hikari Power Ltd, Gates Capital Management Inc., Hikari Tsushin Inc., Roundview Capital Llc.

HEDGE-FUNDS-LIST-DATABASE-FREE Bluestein R H & Co is the most positive hedge fund on Davita Healthcare Partners Inc, with ownership of 10,650 shares as of Q4 2014 for 0.05% of the fund’s portfolio. Dock Street Asset Management Inc is another positive institutional manager having 57,383 shares of the company or 2.29% of their stocks portfolio. The stock is also 1.06% of the fund’s AUM. First Republic Investment Management Inc. have 0.01% of their stock portfolio invested in the company for 7,274 shares. Further, The Massachusetts-based fund Foster Dykema Cabot & Co Inc Ma disclosed it had acquired a stake worth 2.05% of the fund’s stock portfolio in the company. The Illinois-based fund Geneva Advisors Llc was also a big follower of the stock, possessing 5,435 shares. Davita Healthcare Partners Inc is 0.01% of the fund’s stock portfolio.

DaVita HealthCare Partners NYSE:DVA Company Profile

DaVita HealthCare Partners Inc. offers kidney care and manages and operates medical groups. DaVita HealthCare Partners Inc. operates through DaVita Kidney Care and HealthCare Partners (HCP). The Company’s services include outpatient hemodialysis services, hospital inpatient hemodialysis services, Home-based hemodialysis services, ESRD laboratory services and management services. It operates or provides administrative services through a network of outpatient dialysis centers in the United States that are designed for outpatient hemodialysis. The Company provides hospital inpatient hemodialysis services, excluding physician services, to patients in hospitals throughout the United States. DaVita Kidney Care is a provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. HCP manages and operates medical groups and affiliated physician networks in Arizona, California, Nevada, New Mexico, and Florida.

Davita Healthcare Partners Inc was formed in Delaware on 1994-04-04. This company has 57900 employees. As of writing its market cap is: $17.89 billion and it has 216.32 million outstanding shares. Today it has 86.57% shareholders and the institutional ownership is 86.57%. The stock closed at $83.2 yesterday and it had average 2 days volume of 287000 shares. It is up from the 30 days average shares volume of 247747. Davita Healthcare Partners Inc has a 52weeks low of $67.27 and a one year high of $85.17. The stock price is above the 200 days Simple moving average. Davita Healthcare Partners Inc last issued its quarterly earnings report on 05/04/2015. The company reported 0.86 EPS for the quarter, above the consensus estimate of 0.85 by 0.01. The company had a revenue of 3.29 billion for 3/31/2015 and 3.33 billion for 12/31/2014. Therefore, the revenue was -40,052,000 down.

* Shares received upon the satisfaction of performance criteria underlying the awards of performance units.

* The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23 – 2015.

* Represents the weighted average sale price of $81.5006. The range of prices for the sale of these shares was $81.03 – $82.16 – rounded to the nearest hundredths. The reporting person undertakes to provide upon request by the Commission staff – the Issuer – or a security holder of the Issuer – full information regarding the number of shares purchased or sold at each separate price.

...

 
Lehmkuhl increases pressure on ESRD Board to pave Ehmler Lane - The Elsberry Democrat
Lehmkuhl increases pressure on ESRD Board to pave Ehmler Lane - The Elsberry Democrat

Ehmler Acres resident Larry Lehmkuhl addressed the E.S.R.D. Board on May 11 on behalf of himself and his neighbors and asked that Ehmler Lane finally be paved. That request, however, met with no small amount of resistance.

May 11 marked another chapter in the debate over whether or not to chip seal Ehmler Lane, a stretch of road running through the center of Ehmler Acres.

Residents of Ehmler Acres, a neighborhood located off of Hwy. W to the southwest of Elsberry, were represented at the May 11 meeting of the Elsberry Special Road District [E.S.R.D.] by Larry Lehmkuhl.

Lehmkuhl came to the meeting armed with written requests from every resident of Ehmler Acres urging the E.S.R.D. commissioners to finally approve the paving of Ehmler Lane.

Lehmkuhl stated that with oil prices being down the timing couldn’t be better with regard to meeting this request.

“It seems like this would probably be the best time for this to happen,” said Lehmkuhl.

Lehmkuhl added that to put one inch to one and a half inches of gravel on a road one mile long takes 968 tons of rock.

With gravel currently going for $4.50 per ton, the total cost for one application of rock on that same one-mile stretch is $4,356.

To gravel that same stretch twice per year would cost $8,712.

After presenting these figures, Lehmkuhl stated that a road such as Ehmler Lane that isn’t heavily traveled and gets only residential use would hold up with a chip seal surface for between six and eight years before requiring major work again.

He contrasted this with statistics in his possession indicating that the cost to gravel a road for seven years at $4.50 per ton would add up to $60,984.

Lehmkuhl argued that these numbers, combined with the fact that sales tax revenue has increased and new building starts throughout the county are up, make the application of a chip seal surface more affordable now than it has been in some time.

E.S.R.D. Presiding Commissioner Larry Wheeler replied that while he had no personal issues with the idea of paving Ehmler Lane, he wasn’t sure it was the responsible thing to do at this time from a financial standpoint.

Wheeler said the E.S.R.D. has an obligation to first give attention to those roads that are already chip sealed but received no upkeep last year.

He also pointed out that the district has a number of bridges and box culverts that need repair.

These arguments did not discourage Lehmkuhl, however.

“We would like to be moved up to the top of the list since we’ve been trying to get this done for eight years,” said Lehmkuhl.

Commissioner Jackie Briscoe asked Lehmkuhl whether he and the other residents of Ehmler Acres were prepared to chip in some of the costs that would be involved.

Lehmkuhl responded by saying that this was absolutely not an option.

Commissioner Joel Conderman then stated that paving Ehmler Lane would, in his opinion, be like opening Pandora’s Box.

He explained that several months ago when the notion of paving Ehmler Lane was reported in the newspaper, his phone had exploded with calls from angry residents who have been asking for their roads to be paved as well.

Conderman added that the uproar he had been forced to deal with went well beyond the controversy that erupted last year when the board decided to repave portions of Hatfield Road and Old Hwy. 79.

He further stated that the rule currently on the books states that the district is responsible for the maintenance and repair of the roads within its purview in their current form only and that decisions made with regard to paving roads need to be made in line with this policy.

Wheeler agreed and attempted to explain the necessity of such a policy to Lehmkuhl.

That’s where communication broke down, however.

“There is sure a lot of preferential treatment given to certain people living within the Elsberry Special Road District,” said Lehmkuhl. “If you’ve got the right last name you can get all kinds of things done.”

Wheeler denied that this was the manner in which decisions were made and the board subsequently took no action with regard to Lehmkuhl’s request.

In a follow-up interview, Lehmkuhl described the board as reactive rather than proactive and said the decision as to which roads to focus on this year should have been made in March rather than late May or early June.

“They don’t look forward,” said Lehmkuhl. “This is a good time to move forward, be progressive and do something positive for the road district. They could be taking advantage of the relatively low oil prices right now.”

Lehmkuhl said the board’s goal should be to get all of the roads paved and he has no sympathy for their limited funds after the amount of money that he feels was wasted last year on Old Hwy. 79 and Hatfield Road.

Lehmkuhl said that despite the fact that the board has kept him and the other residents of Ehmler Acres running in circles for the last eight years he plans to keep pursuing the issue for as long as it takes.

...

 
<< Start < Prev 121 122 123 124 125 126 127 128 129 130 Next > End >>

Page 123 of 2630
Share |
Copyright © 2024 Global Dialysis. All Rights Reserved.